SG Americas Securities LLC Makes New Investment in scPharmaceuticals Inc. (NASDAQ:SCPH)

SG Americas Securities LLC acquired a new position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 18,558 shares of the company’s stock, valued at approximately $66,000.

A number of other institutional investors have also recently bought and sold shares of SCPH. Suvretta Capital Management LLC acquired a new stake in scPharmaceuticals during the 3rd quarter worth about $9,343,000. Rubric Capital Management LP lifted its holdings in shares of scPharmaceuticals by 35.5% during the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock valued at $21,774,000 after buying an additional 1,250,000 shares during the last quarter. Stonepine Capital Management LLC lifted its holdings in shares of scPharmaceuticals by 84.7% during the 3rd quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock valued at $3,552,000 after buying an additional 357,171 shares during the last quarter. Rice Hall James & Associates LLC lifted its holdings in shares of scPharmaceuticals by 25.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 621,665 shares of the company’s stock valued at $2,835,000 after buying an additional 124,438 shares during the last quarter. Finally, Walleye Capital LLC lifted its holdings in shares of scPharmaceuticals by 27.0% during the 3rd quarter. Walleye Capital LLC now owns 475,555 shares of the company’s stock valued at $2,169,000 after buying an additional 101,148 shares during the last quarter. 89.52% of the stock is currently owned by institutional investors and hedge funds.

scPharmaceuticals Stock Up 6.7 %

Shares of SCPH stock opened at $3.68 on Friday. The stock’s 50 day simple moving average is $3.38 and its 200 day simple moving average is $4.09. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. scPharmaceuticals Inc. has a twelve month low of $3.08 and a twelve month high of $6.54. The company has a market capitalization of $184.15 million, a price-to-earnings ratio of -1.94 and a beta of 0.11.

Wall Street Analysts Forecast Growth

SCPH has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a report on Thursday, November 14th. Craig Hallum cut their price objective on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.